Medindia

X

Reportlinker Adds Top 10 Healthcare Trends in 2011

Wednesday, May 11, 2011 General News J E 4
Advertisement

NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Top 10 Healthcare Trends in 2011

http://www.reportlinker.com/p0491879/Top-10-Healthcare-Trends-in-2011.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Top 10 Healthcare Trends in 2011

Summary

GBI Research has released its latest report, "Top 10 Healthcare Trends in 2011" that provides key data, information and analysis of the major trends in the biopharmaceutical and medical devices industry. The report provides a comprehensive insight into the ten major trends in the biopharmaceutical and medical devices industry in 2011. A detailed analysis of each of the major trends is presented in the report. Major trends in the medical and pharmaceutical industry covered in the report include: Refurbished Systems: Soft Hospital Spending Drives Demand for Refurbished Medical Devices and Capital Equipment, Hospital Information Systems: Government Aid and Cost Savings Driving Development and Adoption, Big Medical Device Companies Turn to Life Sustaining Product Portfolio For Growth, The Regulatory Ecosystem: Changes in the US and Europe to impact industry, The Large Pharmaceutical Companies are Diversifying through Inorganic Growth, Trends in Oncology (the most promising therapeutic market segment) - Market size, forecasts, pipeline analysis, profiles of the most promising molecules under development for each of the major cancer therapeutic segments, Reduction of healthcare costs and drug safety issues will remain the main focus of regulatory authorities and biopharmaceutical industries, Upcoming Sales & Marketing Models will offset the issues/pitfalls of traditional models, Outsourcing Will Remain the Key Strategy for Biopharmaceutical Companies: CRO, CMO And Drug Discovery Outsourcing Will Continue to Grow at a greater pace, and Biologics Price Competition and Innovation Act, 2009 Opens the Gates for Approval of Biosimilars in the US This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research's team of industry experts.

Scope

The report analyses the major trends in biopharmaceutical and medical devices market along with the major forces driving the current market and the potential challenges that can restrain the growth. The Scope of the report includes -

- Detailed overview of strategies and trends of pharmaceutical and medical device industry in 2010.

- Annualized market data, forecast and pipeline analysis for oncology, along with profiles of promising pipeline molecules in lung cancer, breast cancer, colorectal cancer, non-hodgkins lymphoma and prostate cancer.

- Detailed overview of outsourcing strategies and models employed by major pharmaceutical companies and Key strategies and upcoming regulatory changes affecting the industry.

- Overview of the upcoming sales and marketing models in the industry.

- Focus of pharmaceutical industry on healthcare cost reduction and its implications

- Analysis of the regulatory system in the US and Europe.

- Analysis of the key segments that are gaining attention from medical device companies.

- Analysis of partnership deals in 2010 along with segmentation by indication, deal type, geography and companies

- Analysis of M&A deals in 2010 along with segmentation by value geography and companies

Reasons to buy

- Develop market-entry and market expansion strategies by identifying the key therapeutic areas for high growth and high opportunities.

- Understand the factors shaping the pharmaceutical and medical devices market.

- Exploit partnership and acquisition opportunities by identifying the therapy areas/products that could fill the portfolio gaps.

- Align your product portfolio to the markets with high growth potential.

- Identify and develop better strategies and models to ensure better marketing and sales of products.

- Understand the changes in regulatory system and upcoming regulatory models to effectively design clinical trials and/or ensure fast approval of drugs and devices.

- Analyze the trends in licensing and M&A deals and explore potential investment opportunities

- Understand upcoming trends that are poised to drive growth in pharmaceutical and medical devices industry

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 8

1.2 List of Figures 10

2 Top 10 Healthcare Trends in 2011 13

2.1 Introduction 13

2.2 GBI Research Report Guidance 14

3 Refurbished Systems: Soft Hospital Spending Drives Demand for Refurbished Medical Devices and Capital Equipment 15

3.1 Introduction 15

3.2 Standardization and Regulations 15

3.3 Refurbishment Process 15

3.4 Brand Factor 16

3.5 Clean Green Approach 16

3.6 Value Chain Key Driver for Refurbished Systems 16

3.7 Conclusion 17

4 Hospital Information Systems: Government Aid and Cost Savings Driving Development and Adoption 18

4.1 Introduction 18

4.2 Global Hospital Information Systems: Market Characterization 19

4.3 Global Hospital Information Systems: Market Dynamics 20

4.3.1 Key Drivers of Adoption 21

4.4 Global Hospital Information Systems Market: Strategic Competitive Assessment 23

5 Big Medical Device Companies Turn to Life Sustaining Product Portfolio For Growth 24

5.1 Introduction 24

5.2 Company Profiles 25

5.2.1 Medtronic: 25

5.2.2 Boston Scientific: 25

5.2.3 St Jude Medical: 25

5.2.4 Roche 26

5.3 Key Therapeutic Areas 27

5.3.1 Cardiovascular 27

5.3.2 Neurology 34

5.3.3 Diabetes Care Devices: 37

6 The Regulatory Ecosystem: Changes in the US and Europe to impact industry 41

6.1 United States: The 510 (k) Reform 41

6.2 European Union EU Medical Device Directive (MDD) Changes 41

6.2.1 Summary of Changes 41

6.2.2 Impact on the Medical Device Market 41

6.3 Post Marketing Guidance: A Safety Net against Recalls and Safety Issues 42

6.3.1 Summary of Changes 42

6.3.2 Impact on the Medical Device Market 42

6.3.3 Conclusions 42

6.3.4 Key Points: 42

7 The Large Pharmaceutical Companies are Diversifying through Inorganic Growth 43

7.1 Novartis Acquires Alcon 43

7.1.1 Overview 43

7.1.2 Deal Rationale 44

7.1.3 Deal Analysis 44

7.1.4 Company Profile 46

7.2 Abbott Acquires Advanced Medical Optics 46

7.2.1 Overview 46

7.2.2 Deal Rationale 46

7.2.3 Deal Analysis 47

7.2.4 Company Profile 48

7.3 Johnson & Johnson Consolidates Medical Device Portfolio by Acquiring Mentor and Omrix 48

7.3.1 Overview 48

7.3.2 Deal Rationale 48

7.3.3 Deal Analysis 49

7.3.4 Company Profile 51

7.4 Biopharmaceutical companies will continue to extend and expand their portfolio and geographic reach through Mergers, Acquisitions & Licensing Agreements 52

7.4.1 Mergers and Acquisitions 52

7.4.2 Deals by Value 53

7.4.3 Top 10 Mergers and Acquisitions in 2010 54

7.5 Licensing Agreements 55

7.5.1 Deals by Therapy Area 55

7.5.2 Deals by Value 56

7.5.3 Deals by Value 57

8 Pharmaceutical Companies Focus More on Oncology Market Owing to Increased utilization of high-cost targeted and long duration therapies 58

8.1 Introduction 58

8.2 Oncology Therapeutics: Market Overview 58

8.3 The Global Oncology Therapeutics Market Is Expected To Reach Revenues of $33 Billion By 2016 59

8.3.1 Sales Value 59

8.3.2 Avastin, Rituxan and Herceptin are the major selling brands and are expected to lead the market through 2015 60

8.3.3 Increased Interest of Pharmaceutical Companies in Targeted and Customized Therapies 61

8.4 Oncology Therapeutics Market Is Backed By Strong R&D Activity 62

8.5 R&D Trends 65

8.5.1 Discovery of Unknown Mutations that Play Key Role in Cancers 65

8.5.2 Pairing Therapeutics and Diagnostics 66

8.6 Key Late Stage Pipeline Drugs 67

8.6.1 Lung Cancer 67

8.6.2 Breast Cancer 68

8.6.3 Colorectal Cancer 70

8.6.4 Non-Hodgkin's Lymphoma 74

8.6.5 Prostate Cancer 77

9 Outsourcing Will Remain the Key Strategy for Biopharmaceutical Companies: CRO, CMO And Drug Discovery Outsourcing Will Continue to Grow at a greater pace 81

9.1 Introduction 81

9.2 Contract Manufacturing Organizations will receive significant impetus from emerging economies 82

9.3 Contract Manufacturing Organizations (CMO) in Eastern Europe are set to Grow at a Faster Rate 83

9.4 Market Forecasts 85

9.5 Comparative Analysis of Eastern European Countries 86

9.5.1 Infrastructural Facilities – Railways, Roadways, Airways, Power and Overall Logistics Support 87

9.5.2 Labor - Availability of Skilled Labor at Affordable Rates and Labor Flexibility 88

9.5.3 Broad Economic Indicators – GDP, Availability of Credit, Taxation Policies 89

9.5.4 Ease of Doing Business – Overall Government and Regulatory Support 90

9.6 Contract Research Outsourcing Market will continue to Grow, Driven by the Demand by the Biopharmaceutical Industry 92

9.6.1 Introduction 92

9.6.2 Market Characterization 93

9.7 Contract Research Outsourcing Service Model 94

9.7.1 Fully Integrated Service Model 95

9.7.2 Functional Service Model 96

9.8 India and China are the fastest growing markets with regard to drug discovery research 97

9.8.1 Introduction 97

9.8.2 Drug Discovery in India and China – Market Characteristics 98

9.8.3 Why India and China? 99

9.8.4 Availability of Skilled Manpower 99

9.8.5 Scale of Available Resources for Clinical Development 101

9.8.6 Major Therapeutic Areas under Research 101

9.8.7 Improved IP Protection in India and China 102

9.8.8 Government Support for the Drug Discovery Development 103

9.8.9 Risk Sharing Agreements: A Step Forward by Indian and Chinese Companies 105

9.8.10 SWOT Analysis 106

10 Reduction Of Healthcare Costs And Drug Safety Issues Will Remain The Main Focus Of Regulatory Authorities And Biopharmaceutical Industries 108

10.1 Risk Evaluation and Mitigation Strategy (REMS) 108

10.1.1 What is REMS? 108

10.1.2 Risk Evaluation and Mitigation Strategies - Food and Drug Administration Amendments Act (FDAAA) of 2007 109

10.1.3 Components of REMS 109

10.1.4 FDA Approved REMS (2008-2010) 110

10.2 Opioids and REMS 117

10.3 Erythropoiesis-Stimulating Agents (ESAs) 118

10.4 Case Studies 119

10.4.1 Accutane (Isotretinoin) 119

10.4.2 Tysabri (Natalizumab) 120

10.5 Major Players Are Becoming Increasingly Aligned around Personalized Medicine and Companion Diagnostics – Oncology Continues to be the Prime Focus 121

10.6 Global Companion Diagnostics Market, Oncology, Revenue Forecasts ($m), 2009-2016 124

10.7 Biomarkers Facilitate Quick Turnover of Drugs and Significant Reduction in Drug Discovery and Development Costs 127

10.8 The Biomarkers Market Is Forecast To Reach $6.3 Billion By 2016 128

10.8.1 Breast cancer biomarkers contributed to a majority (24%) of the total market revenue 129

10.9 Biomarkers in Cancer Research – Pipeline by Indication 132

11 Upcoming Sales & Marketing Models will offset the issues/pitfalls of traditional models 134

11.1 Introduction 134

11.1.1 Layoff in the Pharmaceutical Companies 134

11.2 Key Account Management Will Be Implemented In All Large and Medium Sized Pharmaceutical Companies 135

11.2.1 Introduction 135

11.2.2 Key Account Management Process 135

11.2.3 Types of Key Account Management 142

11.2.4 Case Studies 143

11.3 Contract Sales Outsourcing Will Increase Due to its Strategic Advantage to Improve Productivity 149

11.3.1 Contract Sales Representatives 150

11.3.2 Sales Team Recruitment and Training 150

11.3.3 Sales Data Analytics and Management 151

11.3.4 Shared Sales Teams and Telesales 151

11.3.5 Medical Science Liaisons 151

11.3.6 The Evolving Model 152

11.3.7 Case Study 153

11.4 Closed Loop Marketing Adoption Has Increased Over the Last Few Years 154

11.4.1 Benefits for Sales & Physicians 155

11.4.2 Benefits for Analytics 155

11.4.3 Benefits for Legal & Regulatory Departments 155

11.4.4 Benefits for Marketing 155

11.4.5 Case Study 155

12 Biologics Price Competition and Innovation Act, 2009 Opens the Gates for Approval of Biosimilars in the US 159

12.1 Biosimilars Approval Pathways in the US and Europe – Market Characterization 159

12.1.1 Global Biosimilar Market Size and Forecast 160

12.1.2 The US Biosimilar Market Size and Forecast 162

12.1.3 Europe Biosimilar Market Size and Forecast 163

12.1.4 Japan Biosimilars Size and Market Forecasts 164

12.2 Biosimilars Approval Pathways in the US and Europe – Drivers and Restraints 165

12.2.1 Drivers 166

12.2.2 Restraints 171

12.3 Market Forecasts for Biosimilars 174

12.3.1 Human Growth Hormone (hGH) Biosimilars Markets 174

12.3.2 Erythropoietin (EPO) Biosimilars Markets 176

12.3.3 Granulocyte – Colony Stimulating Factor (G-CSF) Biosimilars Markets 178

12.4 Opportunity Analysis - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 180

12.4.1 Interferon alfa Biosimilars 180

12.4.2 Interferon beta Biosimilars 182

12.4.3 Insulin and Insulin Analogs Biosimilars 183

12.4.4 TNF alfa Inhibitor Biosimilars 185

12.4.5 Biosimilars for Monoclonal Antibodies against Cancer 186

13 Appendix 189

13.1 Abbreviations 189

13.2 Research Methodology 192

13.2.1 Coverage 192

13.2.2 Secondary Research 192

13.2.3 Primary Research 193

13.2.4 Expert Panel Validation 193

13.3 Contact Us 193

13.4 Disclaimer 193

13.5 Sources 194

1.1 List of Tables

Table 1: Top 10 Trends, Cataract Surgery Devices Market, Global, Revenue ($m) 2009–2016 45

Table 2: Top 10 Trends, Refractive Surgery Devices Market, Global, Revenue ($m) 2009–2016 47

Table 3: Top 10 Trends, Breast Implants Market, Global, Revenue ($m), 2009–2016 49

Table 4: Top 10 Trends, Breast Implants Market ,Global, Company Share (%),2009 50

Table 5: Top 10 Trends, Global Top 10 Mergers and Acquisitions, 2010 54

Table 6: Top 10 Trends, Oncology Therapeutics Market, Global, Market Revenues ($bn), 2002-2009 59

Table 7: Top 10 Trends, Oncology Therapeutics Market, Global, Market Revenues ($bn), 2009-2017 59

Table 8: Top 10 Trends, Oncology Therapeutics Market, Top 10 Brands' Sales ($m), 2006-2009 60

Table 9: Top 10 Trends, Contract Manufacturing Organizations (CMO) in Eastern Europe, Market Characterization, Eastern Europe CMO Market Size, $bn, 2007-2016 85

Table 10: Top 10 Trends, Drug Development Outsourcing Models 94

Table 11: Top 10 Trends, Drug Discovery Market, India and China, Historic Market Size, $bn, 2004–2009 98

Table 12: Top 10 Trends, Drug Discovery Market, India and China, Market Size Forecast, $bn, 2009–2016 98

Table 13: Top 10 Trends, Major Therapeutic Areas of Drug Discovery Research in India and China 102

Table 14: Top 10 Trends, SWOT Analysis – Drug Discovery Market in India and China 106

Table 15: Top 10 Trends, Risk Evaluation and Mitigation Strategy, List of FDA Approved REMS, 2008 110

Table 16: Top 10 Trends, Risk Evaluation and Mitigation Strategy, List of FDA Approved REMS, 2009 111

Table 17: Top 10 Trends, Risk Evaluation and Mitigation Strategy, List of FDA Approved REMS, 2010 114

Table 18: Top 10 Trends, Sales of Personalized Therapeutics ($m), 2007-2009 121

Table 19: Top 10 Trends, Personalized Medicine Market, List of Selected Personalized Diagnostics and Therapeutics, 2010* 123

Table 20: Top 10 Trends, Companion Diagnostics Market, Oncology, Global, Revenues ($m), 2009–2016 125

Table 21: Top 10 Trends, Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007–2016 128

Table 22: Top 10 Trends, Biomarkers in Cancer Research, Global, Breast Cancer Biomarkers Market Revenues ($m), 2007–2016 130

Table 23: Top 10 Trends, Biomarkers in Cancer Research, Global, Prostate Cancer Biomarkers Market Revenues ($m), 2007–2016 131

Table 24: Top 10 Trends, Biomarkers in Cancer Research, Global, Pipeline by Indication and Stage of Development, 2010 133

Table 25: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Market Forecasts, ($m), 2009-2016 160

Table 26: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, the US, Market Forecasts, ($m), 2009–2016 162

Table 27: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Europe, Market Forecasts, ($m), 2009–2016 163

Table 28: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Japan, Market Forecasts, ($m), 2009–2016 164

Table 29: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Comparison for a Biosimilar, 2010 169

Table 30: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Patent Expiry for Major Biologic Drugs, 2010–2016 170

Table 31: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Costs of Development, Manufacturing and Approval of Biosimilars By Cell Culture Type, ($m), 2010 172

Table 32: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, hGH Biosimilars Market Forecasts, ($m), 2009–2016 174

Table 33: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, EPO Biosimilars Market Forecasts, ($m), 2009–2016 176

Table 34: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, G-CSF Biosimilars Market Forecasts, ($m), 2009–2016 178

Table 35: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Interferon alfa Biosimilar Market Opportunity Analysis, ($m), 2009–2016 180

Table 36: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Interferon-beta Biosimilar Market Opportunity Analysis, ($m), 2009–2016 182

Table 37: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Insulin and Insulin Analogs Biosimilar Market Opportunity Analysis, ($m), 2009–2016 183

Table 38: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, TNF alfa Inhibitor Biosimilar Market Opportunity Analysis, ($m), 2009–2016 185

Table 39: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Monoclonal Antibodies Against Cancer Biosimilar Market Opportunity Analysis, ($m), 2009–2016 187

1.2 List of Figures

Figure 1: Top 10 Trends, Hospital Information Systems Market, Global, Revenue Forecast ($m), 2009–2016 19

Figure 2: Top 10 Trends, Global Hospital Information Systems: Market Dynamics 20

Figure 3: Top 10 Trends, Global Hospital Information Systems Key Company Shares (%), 2009 23

Figure 4: Top 10 Trends, Global Cardiovascular Devices Market, Revenue ($bn), 2009–2016 27

Figure 5: Top 10 Trends, Cardiac Rhythm Management, Global, Patient Pool 28

Figure 6: Top 10 Trends, Heart Failure Treatment, Findings of IMPROVE HF Registry (The US), 2005–2009 28

Figure 7: Top 10 Trends, Consolidation in the Electrophysiology Market, Global, Major Acquisitions, 2008–2009 30

Figure 8: Top 10 Trends, Peripheral Vascular Devices Market, Global, Major Acquisitions,2009-2010 31

Figure 9: Top 10 Trends, Cardiovascular Devices Market, Global, Key Company Shares (%), 2009 32

Figure 10: Top 10 Trends, Neurology Devices Market, Global, Revenue ($m), 2009-2016 34

Figure 11: Top 10 Trends, Neurology Devices Market, Global, Company Share (%), 2009 36

Figure 12: Top 10 Trends, Diabetes Care Devices, Revenue ($m), Global, 2009-2016 37

Figure 13: Top 10 Trends, Diabetes Care Devices, Global, Company Share (% in Revenue), 2009 40

Figure 14: Top 10 Trends, Cataract Surgery Devices Market, Global, Revenue ($m) 2009–2016 45

Figure 15: Top 10 Trends, Refractive Surgery Devices Market, Global, Revenue ($m) 2009–2016 47

Figure 16: Top 10 Trends, Breast Implants Market, Global, Revenue ($m), 2009–2016 49

Figure 17: Top 10 Trends, Breast Implants Market , Global, Company Share (%), 2009 50

Figure 18: Top 10 Trends, Global, M&A, By Therapy Area, 2010 52

Figure 19: Top 10 Trends, Global, M&A Deals, By Value, 2010 53

Figure 20: Top 10 Trends, Global, Licensing Agreements, By Therapy Area, 2010 55

Figure 21: Top 10 Trends, Global, Licensing Agreements, By Value ($m), 2010 56

Figure 22: Top 10 Trends, Global, Licensing Agreements, By Value ($m), 2010 57

Figure 23: Top 10 Trends, Oncology Therapeutics Market, Global, Market Revenues ($bn), 2002-2017 59

Figure 24: Top 10 Trends, Oncology Therapeutics Market, Top 10 Brands' Sales ($m), 2006-2009 60

Figure 25: Top 10 Trends, Oncology Therapeutics Market, Global, Key Targeted Therapies Launched, 1998-2009 61

Figure 26: Top 10 Trends, Global, Pipeline By Therapy Area, 2010 63

Figure 27: Top 10 Trends, Global Oncology Therapeutics, Pipeline By Indication, 2010 64

Figure 28: Top 10 Trends, Global Oncology Therapeutics, Pipeline By Indication and Phase, 2010 64

Figure 29: Top 10 Trends, Increasing Share of CMOs in Overall Pharmaceutical Manufacturing 82

Figure 30: Top 10 Trends, Revenue Split of Global CMO Market by Geography 83

Figure 31: Top 10 Trends, Break-up of Global CMO Market by Services Provided 84

Figure 32: Top 10 Trends, Contract Manufacturing Organizations (CMO) in Eastern Europe, Market Characterization, Eastern Europe CMO Market Size ($bn), 2007-2016 85

Figure 33: Top 10 Trends, Parameters Considered for Ranking of Different Eastern European Nations 86

Figure 34: Top 10 Trends, Ranking on Infrastructure of Different Eastern European Nations 87

Figure 35: Top 10 Trends, Rankings for Attractiveness of Labor of Different Eastern European Nations 88

Figure 36: Top 10 Trends, Rankings for Broad Economic Indicators of Different Eastern European Nations 89

Figure 37: Top 10 Trends, Rankings for Ease of Doing Business for Different Eastern European Nations 90

Figure 38: Top 10 Trends, Ranks for Overall Business Attractiveness 91

Figure 39: Top 10 Trends, Global Contract Research Outsourcing Market Forecasts, 2006-2015 93

Figure 40: Top 10 Trends, Contract Research Outsourcing – Fully Integrated Service Model 95

Figure 41: Top 10 Trends, Contract Research Outsourcing – Functional Service Model 96

Figure 42: Top 10 Trends, Drug Discovery Market, India and China, Market Size, $bn, 2004–2016 98

Figure 43: Top 10 Trends, India & China Talent Pool – Comparison 99

Figure 44: Top 10 Trends, Top 5 Nationalities of Foreign Inventors Named in the PCT (Patent Cooperation Treaty) International Applications Filed, 2008 100

Figure 45: Top 10 Trends, Risk-Sharing Model Between Western Pharma Companies and Indian/Chinese Companies 105

Figure 46: Top 10 Trends, Risk Evaluation and Mitigation Strategy, Requirement of additional REMS component, 2008-2010 116

Figure 47: Top 10 Trends, REMS, Erythropoiesis-Stimulating Agents, Case Study, 2010 118

Figure 48: Top 10 Trends, REMS, Accutane Case Study, 2010 119

Figure 49: Top 10 Trends, REMS, Tysabri Case Study, 2010 120

Figure 50: Top 10 Trends, Personalized Medicine Market, Potential Applications of Personalized Medicine 122

Figure 51: Top 10 Trends, Companion Diagnostics Market, Oncology, Global, Revenue ($m), 2009–2016 124

Figure 52: Top 10 Trends, Companion Diagnostics Market, Herceptin Prescription Pattern, 2010 125

Figure 53: Top 10 Trends, Personalized Medicine Market, Biomarkers in Cancer Research, 2010 127

Figure 54: Top 10 Trends, Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007–2016 128

Figure 55: Top 10 Trends, Biomarkers in Cancer Research, Global, Market Segmentation by Indication, 2009 129

Figure 56: Top 10 Trends, Biomarkers in Cancer Research, Global, Breast Cancer Biomarkers Market Revenues ($m), 2007–2016 130

Figure 57: Top 10 Trends, Biomarkers in Cancer Research, Global, Prostate Cancer Biomarkers Market Revenues ($m), 2007–2016 131

Figure 58: Top 10 Trends, Biomarkers in Cancer Research, Global, Pipeline by Indication (%), 2010 132

Figure 59: Top 10 Trends, Pharmaceutical Industry, Global, Layoffs by Pharmaceutical Companies, 2010 134

Figure 60: Top 10 Trends, KAM Process, 2010 136

Figure 61: Top 10 Trends, Key Accounts Identification and Prioritization, Risk vs. Potential 137

Figure 62: Top 10 Trends, Key Accounts Identification and Prioritization, Skill vs. Will 138

Figure 63: Top 10 Trends, Key Accounts Primary Selection Criteria 138

Figure 64: Top 10 Trends, Understanding Needs and Developing Customer Insights 140

Figure 65: Top 10 Trends, Forming the Account Team 140

Figure 66: Top 10 Trends, Developing Key Account Strategic Plan 141

Figure 67: Top 10 Trends, Communicating and Implementing the Key Account Strategic Plan 141

Figure 68: Top 10 Trends, Reviewing KAM Results 142

Figure 69: Top 10 Trends, Lundbeck and KAM Principle, 2010 143

Figure 70: Top 10 Trends, Abbott's Sales Force Optimization 144

Figure 71: Top 10 Trends, Abbott's Account Strategy, 2010 145

Figure 72: Top 10 Trends, Segmentation and Targeting Strategy of Abbott, 2010 146

Figure 73: Top 10 Trends, Calculating Account Value, 2010 147

Figure 74: Top 10 Trends, Positioning the Key Accounts 148

Figure 75: Top 10 Trends, Contract Sales Organizations – Major Services, 2010 149

Figure 76: Top 10 Trends, Contract Sales Organizations and Evolving Sales Model 152

Figure 77: Top 10 Trends, CLM Enabled Commercial Organization, 2010 154

Figure 78: Top 10 Trends, Wyeth's Target Selection Model, 2010 156

Figure 79: Top 10 Trends, Wyeth's Segmentation Model, 2010 156

Figure 80: Top 10 Trends, Benefits of CLM for Wyeth, 2010 157

Figure 81: Top 10 Trends, Customer Response Framework for CLM, 2010 157

Figure 82: Top 10 Trends, Customer Response Success Rate for CLM, 2010 158

Figure 83: Top 10 Trends, Wyeth and its CLM Process, 2010 158

Figure 84: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Market Forecasts, ($m), 2009-2016 160

Figure 85: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, the US, Market Forecasts, ($m), 2009–2016 162

Figure 86: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Europe, Market Forecasts, ($m), 2009-2016 163

Figure 87: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Japan, Market Forecasts, ($m), 2009–2016 164

Figure 88: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Drivers and Restraints, 2010 165

Figure 89: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Rising Expenditure on Pharmaceuticals, 2010 166

Figure 90: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Increase in Elderly Population Indicates Rising Healthcare Expenses, 2010 167

Figure 91: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Inflation in Prescription Drug Prices in the US , 2010 168

Figure 92: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Costs of Development, Manufacturing and Approval of Biosimilars by Cell Culture Type, ($m), 2010 172

Figure 93: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, hGH Biosimilars Market Forecasts, ($m), 2009–2016 174

Figure 94: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, EPO Biosimilars Market Forecasts, ($m), 2009–2016 176

Figure 95: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, G-CSF Biosimilars Market Forecasts, ($m), 2009–2016 178

Figure 96: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Interferon alfa Biosimilar Market Opportunity Analysis, ($m), 2009–2016 180

Figure 97: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Interferon beta Biosimilar Market Opportunity Analysis, ($m), 2009–2016 182

Figure 98: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Insulin and Insulin Analogs Biosimilar Market Opportunity Analysis, ($m), 2009–2016 183

Figure 99: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, TNF alfa Inhibitor Biosimilar Market Opportunity Analysis,($m), 2009–2016 185

Figure 100: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Monoclonal Antibodies Against Cancer Biosimilar Market Opportunity Analysis, ($m), 2009–2016 187

Figure 101: Top 10 Trends, Biosimilars Approval Pathways in the US and Europe, Global, Expected Market Split in 2016 188

Companies mentioned

Medtronic

Boston Scientific

St Jude Medical

Roche

To order this report:

In Vitro Diagnostic Industry: Top 10 Healthcare Trends in 2011

In Vitro Diagnostic Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Vemurafenib New Drug Application Submitted to FDA ...
S
National Veterans Foundation Launches WhatIsTBI.or...